Physician profile
Norman E Pahmeier
NPI 1619065083
$767.45
in general payments reported to CMS, 2019-2025
15 companies · $287 in 2025
The $287 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.84 · 2020: $58.74 · 2021: $110 · 2022: $154 · 2023: $59.55 · 2024: $36.45 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $225.28 | 2021-2025 | Tecnis Simplicity, Amo Phaco Needle |
| Lumenis Be INC | $138.99 | 2025 | M22 |
| Shire North American Group INC | $61.84 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $45.89 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $43.25 | 2020-2021 | |
| Astellas Pharma US INC | $36.33 | 2025 | Izervay |
| Abbvie INC. | $33.06 | 2023 | |
| Dompe US, INC. | $31.89 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $31.81 | 2022-2025 | Xiidra, Miebo |
| Alcon Vision LLC | $31.19 | 2025 | Clareon |
| Carl Zeiss Meditec USA, INC. | $26.49 | 2023 | Cirrus Hd-Oct |
| Sun Pharmaceutical Industries INC. | $19.21 | 2024 | |
| Allergan, INC. | $15.81 | 2020 | |
| Biotissue Holdings INC. | $13.60 | 2025 | |
| Eyevance Pharmaceuticals LLC | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Pahmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.